Kenvue (NYSE:KVUE) Price Target Lowered to $21.00 at Bank of America

Key Points

• Bank of America has lowered its price target for Kenvue from $25.00 to $21.00, while maintaining a "buy" rating, indicating a potential upside of 30.56% from current levels.
• Other analysts, including Royal Bank of Canada and Goldman Sachs, have also reduced their price targets for Kenvue, reflecting a cautious outlook on the company.
• Kenvue's stock performance shows recent trading at $16.09, down from highs of $25.17, with a current market cap of $30.87 billion.

Kenvue (NYSE:KVUE - Get Free Report) had its price objective reduced by Bank of America from $25.00 to $21.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Bank of America's target price points to a potential upside of 30.56% from the company's current price.

Several other equities research analysts have also recently commented on the company. Royal Bank Of Canada cut their price target on Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. Canaccord Genuity Group cut their price target on Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Redburn Partners set a $22.00 price target on Kenvue in a research note on Friday, September 26th. UBS Group cut their price target on Kenvue from $23.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday. Finally, The Goldman Sachs Group cut their price objective on Kenvue from $22.00 to $19.00 and set a "neutral" rating for the company in a research report on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $21.75.

Kenvue Stock Performance

NYSE KVUE traded down $0.14 on Wednesday, reaching $16.09. The stock had a trading volume of 12,231,936 shares, compared to its average volume of 20,309,609. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. Kenvue has a 12-month low of $15.47 and a 12-month high of $25.17. The business's 50-day moving average price is $19.46 and its 200 day moving average price is $21.46. The stock has a market cap of $30.87 billion, a P/E ratio of 21.74, a price-to-earnings-growth ratio of 2.25 and a beta of 0.72.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. During the same quarter in the previous year, the business earned $0.32 earnings per share. The firm's revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts expect that Kenvue will post 1.14 earnings per share for the current year.

Institutional Trading of Kenvue

Hedge funds have recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. boosted its stake in Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after buying an additional 4,034 shares during the last quarter. Renaissance Capital LLC lifted its stake in shares of Kenvue by 8.3% in the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company's stock valued at $13,169,000 after purchasing an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Kenvue by 80.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company's stock valued at $758,000 after purchasing an additional 16,164 shares in the last quarter. Arlington Partners LLC acquired a new position in shares of Kenvue in the 2nd quarter valued at about $2,110,000. Finally, Cornell Pochily Investment Advisors Inc. lifted its stake in shares of Kenvue by 144.6% in the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company's stock valued at $694,000 after purchasing an additional 19,609 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.